Skip to main content
Premium Trial:

Request an Annual Quote

Genome X Prize Names SAB Member; Venter Leaves US Genomics' Board; Qiagen Nominates von Prondzynski to Board; and Others

This article has been updated to correct several errors in the item about Qiagen's supervisory board elections. Heino von Prondzynski and Werner Brandt are standing for election for the supervisory board, not the board of directors. In addition von Prondzynski and Brandt are not retiring from the board.
 
NEW YORK (GenomeWeb News) — The X Prize Foundation has appointed Leena Peltonen to the scientific advisory board of the Archon X Prize for Genomics.
 
Peltonen is a professor at the University of Helsinki and at the National Public Health Institute in Finland, and is a visiting professor at the Broad Institute of MIT and Harvard.

US Genomics last week said Craig Venter has stepped down from its board of directors and that Salvatore Salamone has joined it.
 
Salamone is currently chairman and CEO of Saladax BioMedical, a developer of chemotherapy-monitoring assays. Previously, he was vice president of R&D at Roche Diagnostics and senior vice president of R&D at Orasure Technologies.

Qiagen has nominated Heino von Prondzynski and Werner Brandt to the company’s supervisory board. They will stand for election at Qiagen’s annual meeting June 20.
 
Also at that meeting, Franz Wirtz and Heinrich Hornef will retire from their long-held positions on the company’s supervisory board.
 
Prondzynski was CEO of Roche Diagnostics and a member of Roche’s executive committee and was CEO and general manager at Chiron.
 
Brandt was chief financial officer at SAP and was a member of SAP’s executive board. He also was CFO of Frenesius Medical Care and formerly worked in finance at Price Waterhouse Coopers.

 
Ciphergen has named Steve Lundy senior vice president of sales and marketing, the company said this week.
 
Lundy comes to Ciphergen from GeneOhm, where he was vice president of sales and marketing. He had worked earlier as vice president of marketing at Esoterix and was marketing director of molecular diagnostics and critical care testing at Bayer Diagnostics.

 
Upstream Biosciences has appointed Edward Kiruluta to its scientific advisory board. Kiruluta is currently vice president of engineering at DemandTec, where he runs the company’s econometrics, optimization, and database teams.
 
Kiruluta previously was a senior director of informatics at Merck Research Labs, and was chief technology officer and vice president at DoubleTwist.

 
Pathwork Diagnostics has appointed W. David Henner chief medical officer, and it has named David Craford vice president of commercial operations.
 
Henner formerly was vice president of oncology at Novacea and Craford has been vice president of business development at Affymetrix.

 
Thermo Fisher Scientific has named Jim Manzi non-executive chairman of the board, the company said this week.
 
Manzi takes over from Paul Meister, who retired in April.
 
Manzi was chairman from December 2003 to November 2006 when Thermo
Electron closed its merger with Fisher Scientific.
 
Manzi currently is chairman of Stonegate Capital, and has been chairman, president, and CEO of Lotus Development.

Bruker BioSciences has elected Wolf-Dieter Emmerich, Brenda Furlong, and Richard Packer to its board as independent directors, the company said this week. The appointments last three years.
 
Bruker also reelected CEO Frank Laukien to the board.
 
Emerich was general manager and a director of Netzsch Thermal Analysis. Furlong was a managing director at Columbia Management, a division of Bank of America, and was chief investment officer of Hartford Financial Services. Packer, who will serve on Bruker’s audit committee, is chairman and CEO of Zoll Medical, and is on the steering committee at the Massachusetts Life Sciences Initiative.

 
William Gerber resigned from his non-independent position on Nanogen’s board on May 1, the company said this week.
 
The company said the resignation brings Nanogen back into compliance with a Nasdaq listing rule governing the number of independent directors a company must have on its board.
 
The company lost its Nasdaq compliance on that rule when it named FasTraQ CEO Heiner Dreismann to another non-independent position.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.